Navigation Links
Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
Date:11/29/2011

o add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's expectations that data from the first Phase 3 trial of OMS302 will be available during the first quarter of 2012, that Omeros will initiate a second Phase 3 trial of OMS302 following discussions with regulators, that Omeros will be poised to file marketing applications as soon as possible following receipt of OMS302 Phase 3 clinical data , and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Reportlinker.com announces that a new market ... Portugal Pharmaceuticals and Healthcare Report Q3 ... Includes 3 FREE quarterly updates ... last quarter has led us to revise our ... previously, BMI expects Portugal,s ...
(Date:7/28/2014)... CLEVELAND , July 28, 2014  Surgical ... new members to its Business Advisory Board. New ... Senior Vice President for Business Development and New ... (Jim) Fulton , former Senior Vice President and ... unit. Surgical Theater applies flight simulation technology to ...
(Date:7/28/2014)... , July 28, 2014  Serco Inc., a ... the Company has been awarded a re-compete contract ... (NEMSCOM) and its Deployable Medical Systems.  Serco will ... personnel to provide world-class healthcare to meet warfighter ... across the globe. The five year contract has ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... , ATLANTA, Dec. 23 MiMedx Group, Inc. ... launched its first product, Paradis Vaso Shield(TM). In April ... for use as a cover for vessels following anterior vertebral ... hydrogel product protected by multiple patents and patent applications, as ...
... FRANCISCO, Dec. 23 Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing ... that management will present at the following upcoming investor conferences. , ... January 12, 2010, 9:40 a.m. PT, ... OneMedForum 2010, Wednesday, January 13, 2010, ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... Research into improving treatment for patients with one of ... 810,000 funding boost. , Chronic obstructive pulmonary disease (COPD) ... cause breathing difficulties due to long-term damage to the ... for 10 per cent of all hospital admissions in ... readmitted to hospital after they are discharged. ...
(Date:7/28/2014)... Malibu, CA (PRWEB) July 28, 2014 ... upon us, it is welcome news that a ... effective than current protection is under development by SunSeeker ... by NASA to protect spacecraft from the extreme heat ... protection to both firefighters and homes. , “Our firefighters ...
(Date:7/28/2014)... 28, 2014 Drorit Silverman, a professional ... plans to raise investment capital through her crowd funding ... in the United States. , According to a statement ... fitness centers provide a great window of opportunity for ... space. In addition to this, Silverman looks at the ...
(Date:7/28/2014)... (Boston)-- Researchers from Boston University School of Medicine (BUSM) ... increase the risk of developing Alzheimer,s disease (AD). The ... new drug treatment options that target PLXNA4 specifically. These ... , AD is the most frequent age-related dementia affecting ... 65 and older, and more than 40 percent of ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Researchers identify potential biomarker for AD 2
... and Treatment Centers Seek Competitive Advantage by Leveraging ... to make ends meet, the ability to do ... gain efficiencies comes from two converging market forces: ... recession-proof healthcare industry, and the national push to ...
... will be made available closer to the meeting date. ... the meeting as well as during the meeting. , ... Council of the National Academy of Sciences. The Society,s ... and to encourage applications of research findings. Its membership ...
... QC, April 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... the results of its recently completed North American ... of tramadol and acetaminophen (study 06CCL3-001). , Study ... that compared the efficacy and safety of Labopharm,s ...
... connect, exchange information and ,speak, HL7. , ... Toronto, ... - a core need in modern healthcare - has never been ... HL7 Interface Engine . This easy-to-use yet powerful tool, ...
... through common symptoms during pregnancy, such as morning sickness, fatigue and weight ... when they come. At Gurgle, we offer a guide to women in ... , ... London, England (PRWEB) April 2, 2009 -- Around half of ...
... NY -- Biomedical informatics researchers at Mayo Clinic ... the newly founded Open Health Natural Language Processing ... space to promote past and current development efforts, ... records. , As part of the launch, Mayo ...
Cached Medicine News:Health News:Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies 2Health News:Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies 3Health News:Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation 2Health News:Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation 3Health News:Talking Iguana - Helping the Healthcare Sector Speak HL7 2Health News:Talking Iguana - Helping the Healthcare Sector Speak HL7 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Mayo Clinic and IBM host medical language initiative 2Health News:Mayo Clinic and IBM host medical language initiative 3Health News:Mayo Clinic and IBM host medical language initiative 4
...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: